Ardelyx (ARDX)

• Market cap: $785M
• 1 day: -3.24%
• 5 days: -10.38%
• 1 month: -28.23%
• 3 months: -43.35%
• 6 months: -30.36%
• Year to date: -35.94%
• 1 year: -57.89%
• 5 years: -54.38%
• 10 years: -63.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 395

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

35% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 34

18% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 62

4% more funds holding

Funds holding: 201 [Q3] → 210 (+9) [Q4]

3.09% more ownership

Funds ownership: 60.59% [Q3] → 63.68% (+3.09%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

22% less capital invested

Capital invested by funds: $982M [Q3] → $765M (-$218M) [Q4]

23% less call options, than puts

Call options by funds: $14.5M | Put options by funds: $18.9M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5.50 68% upside
• Avg. target: $10.90 232% upside
• High target: $15 357% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Citigroup Yigal Nochomovitz 11% 1-year accuracy 4 / 36 met price target	205% upside $10	Buy Maintained	2 May 2025
Scotiabank Louise Chen 23% 1-year accuracy 26 / 113 met price target	357% upside $15	Sector Outperform Initiated	7 Mar 2025
Ladenburg Thalmann Aydin Huseynov 14% 1-year accuracy 1 / 7 met price target	235% upside $11	Buy Assumed	7 Mar 2025
Raymond James Ryan Deschner 91% 1-year accuracy 10 / 11 met price target	296% upside $13	Strong Buy Reiterated	21 Feb 2025
HC Wainwright & Co. Ed Arce 41% 1-year accuracy 57 / 140 met price target	68% upside $5.50	Neutral Reiterated	21 Feb 2025